CDMS: Lowering end user costs of NCD medication


CDMS (“Chronical Drugs Medical Scheme”) aggregates the demand of small and medium-sized hospitals for NCD drugs in order to decrease procurement costs and obtain quantity discounts from pharmaceutical companies and wholesalers. In order to enable patients to benefit from the lower drug prices, CDMS also offers a pre-screening program. This way, high-risk patients in the community are identified and those with elevated blood pressure and sugars are referred to a precontracted ‘hub’ hospital where they benefit from the lower costs.

The venture builds upon the business model that CDMS receives a commission fee on NCD medication from the hospitals.

CDMS is a registered social enterprise in Kenya. Since they piloted in 2019, they have achieved reducing the price of NCD medicines by 18% for their currently more than 230 partner hospitals. Moreover, more than 8.000 pre-screenings could be executed, diagnosing hypertension in over 25% of the cases. CDMS has also developed an eCommerce platform to register hospitals and distributors there and works on a training program for hospital staff.

 

Developed in lot 5 // Challenge: How might we improve chronic disease prevention and control in Kenya?

Team: Boehringer Ingelheim, Making more health, Ashoka

More information: Chronic Drugs Medical Scheme (CDMS)

Share this